Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria

Encorafenib Plus Binimetinib in Patients With Locally Advanced, Unresectable or Metastatic BRAFV600-mutated Melanoma: a Multi-centric, Multinational, Prospective, Longitudinal, Non-interventional Study in Germany, Austria and Switzerland

Evaluierung der adjuvanten Therapie beim Dickdarmkrebs im Stadium II nach ctDNA-Bestimmung

Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)

A randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

A Phase II, multicenter, open-Label, randomized-controlled Trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti- PD-L1 antibody atezolizumab for the Treatment in patients with unresectable or metastatic BRAF V600 Mutant melanoma ImmunoCobiVem.

Efficacy Comparison of Dostarlimab Plus Chemotherapy vs Pembrolizumab plus Chemotherapy in Participants with metatstatic non-squamous non-small Cell Lung